Abstract
I read with interest the Journal's recent publication of the PLACE trial, comparing half-dose photodynamic therapy with micropulse laser treatment for central serous chorioretinopathy. 1 van Rijssen T.J. van Dijk E.H.C. Scholz P. et al. Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE Trial Report No. 3. Am J Ophthalmol. 2019; 205: 1-10 Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar In report no. 3, the author notes that the study has been criticized for inadequate treatment of the micropulse arm. 2 Battaglia Parodi M. Iacono P. Re: van Dijk et al.: Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial (Ophthalmology. 2018;125:1547-1555). Ophthalmology. 2019; 126: e29-e30 Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar He answers by stating that the deficiency in treatment area and density (number of laser spots) is made up for by the unprecedentedly high laser power employed. 1 van Rijssen T.J. van Dijk E.H.C. Scholz P. et al. Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE Trial Report No. 3. Am J Ophthalmol. 2019; 205: 1-10 Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3American Journal of OphthalmologyVol. 205PreviewTo compare the outcome between high-density subthreshold micropulse laser (HSML) treatment and half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (cCSC) patients, subdivided based on either focal or diffuse leakage on fluorescein angiography (FA). Full-Text PDF Reply to Comment on: Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3American Journal of OphthalmologyVol. 212PreviewWe thank the author for his interest and recent letter regarding our study on the effects of half-dose photodynamic therapy (PDT) and high-density subthreshold micropulse laser (HSML) in chronic central serous chorioretinopathy (CSC) with focal and diffuse leakage.1 Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
